(1S,3S,4R,5S)-3,4,5-trihydroxypipecolic acid | 129797-28-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,3S,4R,5S)-3,4,5-trihydroxypipecolic acid
• 英文别名: (2S,3S,4R,5S)-3,4,5-trihydroxypipecolic acid；(2S,3S,4R,5S)-trihydroxypipecolic acid；1-deoxy-5-aza-D-galactopyranuronic acid；2,6-dideoxy-2,6-imino-L-galactonic acid；Rzf4F8M7AZ；(2S,3S,4R,5S)-3,4,5-trihydroxypiperidine-2-carboxylic acid
• CAS: 129797-28-0
• 化学式: C₆H₁₁NO₅
• 分子量: 177.157
• InChiKey: ZHFMVVUVCALAMY-KLVWXMOXSA-N

物化性质

• 熔点：
  270 °C (decomp)
• 沸点：
  442.1±45.0 °C(Predicted)
• 密度：
  1.676±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (3S,6R,1'S,2'S,3'S)-3-(1-benzyloxy-4-hydroxy-2,3-isopropylidenedioxybutyl)-2,5-diethoxy-3,6-dihydro-6-isopropylpyrazine 在 palladium on activated charcoal 盐酸 、 4-二甲氨基吡啶 、 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 21.0h， 生成 (1S,3S,4R,5S)-3,4,5-trihydroxypipecolic acid
  参考文献：
  名称：

  Amino and hydroxy acid based diastereoselective synthesis of 1-deoxygalactostatin and its imino acid derivative

  摘要：

  1-Deoxygalactostatin (2) and (2S, 3S, 4R, 5S)-trihydroxypipecolic acid (15) have been synthesised from known building blocks derived from glycine, D-valine and L-tartaric acid (eight and seven steps, with 23% and 27% yield, respectively), via a syn-aldol reaction between 4-O-(tert-butyldiphenylsilyl)-2,-O-isopropylidene-L-threose (6) and the stannous salt of the Schollkopf's bislactim ether 7b. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(99)00107-0

文献信息

• Synthesis of both enantiomers of hydroxypipecolic acid derivatives equivalent to 5-azapyranuronic acids and evaluation of their inhibitory activities against glycosidases
  作者：Yuichi Yoshimura、Chiaki Ohara、Tatsushi Imahori、Yukako Saito、Atsushi Kato、Saori Miyauchi、Isao Adachi、Hiroki Takahata

  DOI：10.1016/j.bmc.2008.06.016

  日期：2008.9

  kinetic resolution, the synthesis of both L- and D-isomers of 3,4,5-trihydroxy- and 3-hydroxypipecolic acids was achieved. None of the compounds tested showed inhibitory activity against alpha- and beta-glucosidases. On the other hand, L-23 and L-29 were found to have potent inhibitory activity against beta-glucuronidase. In addition, it is interesting that some uronic-type azasugar derivatives showed moderate

  我们已经合成了对应于糖醛酸的5-氮杂衍生物的3-羟基-和3,4,5-三羟基哌酸衍生物，并评估了它们对包括β-葡萄糖醛酸苷酶在内的各种糖苷酶的抑制活性。选择化合物4和5作为合成3,4,5-三羟基哌酸和3-羟基哌酸以及3-羟基贝白蛋白（从有毒蘑菇中分离出的独特天然产物）的常用中间体。N-Boc-烯丙基甘氨酸衍生物与丙烯醛的交叉羟醛缩合反应，然后进行闭环易位，得到非对映异构体混合物的4和5，可以通过硅胶柱色谱法分离。通过使用脂肪酶催化的动力学拆分，可以合成3,4,5-三羟基和3-羟基哌酸的L-异构体和D-异构体。所测试的化合物均未显示出对α-和β-葡糖苷酶的抑制活性。另一方面，发现L-23和L-29对β-葡糖醛酸糖苷酶具有有效的抑制活性。另外，有趣的是，一些糖醛酸型的氮杂糖衍生物显示出对β-N-乙酰氨基葡糖苷酶的中等抑制活性。
• Diastereoselective Synthesis of Piperidine Imino Sugars Using Aldol Additions of Metalated Bislactim Ethers to Threose and Erythrose Acetonides
  作者：María Ruiz、Tania M. Ruanova、Olga Blanco、Fátima Núñez、Cristina Pato、Vicente Ojea

  DOI：10.1021/jo702601z

  日期：2008.3.1

  anti-selectivity for the mismatched ones may originate from (1) the intervention of solvated aggregates of tin(II) azaenolate and lithium chloride as the reactive species and (2) favored chair-like transition structures with a Cornforth-like conformation for the aldehyde moiety. DFT calculations indicate that aldol additions to erythrose acetonides proceed by an initial deprotonation, followed by coordination

  描述了从手性甘氨酸当量和4-碳构件合成1-脱氧-天冬酰胺的一般策略。非对映选择性醛醇缩合的金属化双lactimin醚添加到匹配和不匹配的赤藓糖或苏糖酸丙酮化物和分子内氮-烷基化（通过还原胺化或亲核取代）被用作关键步骤。研究了赤藓糖或苏糖醛丙酮化物中氮杂烯酸酯的金属抗衡离子和γ-烷氧基保护基的性质和醛醇加成的收率和不对称诱导的关系。借助密度泛函理论（DFT）计算已经合理化了氮杂锡（II）锡与羟醛加成的立体化学结果。按照理论计算与模型甘油丙酮化，高反式，顺式，反-selectivitity的配对和适度低反式，反，反错配的选择性可能源于（1）干预作为活性物质的氮杂锡（II）和氯化锂（II）的溶剂化团聚体；（2）醛基具有类似于Cornforth构象的椅子样过渡结构。DFT计算表明，向赤藓糖醇丙酮中添加羟醛的过程是先进行去质子化，然后将烷氧基衍生物与氮杂锡（II）配位，并通过周环过渡结构最终重组中间
• Regioselective intramolecular ring closure of 2-amino-6-bromo-2,6-dideoxyhexono-1,4-lactones to 5- or 6-membered iminuronic acid analogues: synthesis of 1-deoxymannojirimycin and 2,5-dideoxy-2,5-imino-d-glucitol
  作者：Birgitte M. Malle、Inge Lundt、Tanja M. Wrodnigg

  DOI：10.1039/b719631h

  日期：——

  aqueous base at pH 12, ring closure took place by 5-exo attack on the 5,6-epoxide leading to 2,5-dideoxy-2,5-imino-L-gulonic acid (9b), which was reduced to 2,5-dideoxy-2,5-imino-D-glucitol (9b). The method was further applied to 2-amino-6-bromo-2,6-dideoxy-D-galacto- as well as D-talo-1,4-lactones (14 and 15). However, only the corresponding six-membered ring 1,5-iminuronic acid mimetics, namely (2R

  1-脱氧甘露糖霉素（8c）是由2-氨基-6-溴-2,6-二脱氧-D-甘露糖-1,4-内酯（7）通过分子内直接取代C-6溴的非水碱合成的处理，然后还原中间体甲酯。同样，使用pH值为12的碱水溶液，通过5-环氧对5,6-环氧的进攻，使环闭合，从而生成2,5-二脱氧-2,5-亚氨基-L-古洛糖酸（9b）至2，5-二脱氧-2，5-亚氨基-D-葡萄糖醇（9b）。该方法进一步应用于2-氨基-6-溴-2,6-二脱氧-D-半乳糖以及D-talo-1,4-内酯（14和15）。但是，只有相应的六元环1,5-亚氨基尿酸模拟物，即（2R，3R，4S，5R）-3,4,5-三羟基哌酸（2,6-dideoxy-2,6-imino-D -半乳糖酸16）和（2S，3R，4S，5R）-3,4,5-三羟基哌酸（2,6-dideoxy-2,6-imino-D-talonic acid，17），获得了。相应的对映异构体L-半乳酸酯以及L-talo-2-氨基-6-溴2
• Inhibition of plant glycosidases by a D-galacturonic acid analog
  作者：Michael K. Tong、Edward M. Blumenthal、Bruce Ganem

  DOI：10.1016/s0040-4039(00)88853-x

  日期：——

  A simple synthesis of the aza-analog 7 of D-galacturonic acid 8 from D-galactose is reported.

  据报道由D-半乳糖简单合成D-半乳糖醛酸8的氮杂类似物7。
• Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same
  申请人：Amicus Therapeutics, Inc.

  公开号：US20220185776A1

  公开（公告）日：2022-06-16

  Provided are methods of producing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of determining the purity of a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of distributing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of assessing suitability of migalastat hydrochloride for medical use.